INCLUSION BODY MYOSITIS
Clinical trials for INCLUSION BODY MYOSITIS explained in plain language.
Never miss a new study
Get alerted when new INCLUSION BODY MYOSITIS trials appear
Sign up with your email to follow new studies for INCLUSION BODY MYOSITIS, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
Can a transplant drug slow rare muscle disease?
Disease control OngoingThis phase 3 trial tests whether sirolimus, a drug used in organ transplants, can slow or stop muscle decline in people with inclusion body myositis (IBM), a rare muscle disease. About 140 adults aged 45 and older will take sirolimus or a placebo for 84 weeks. The study measures …
Matched conditions: INCLUSION BODY MYOSITIS
Phase: PHASE3 • Sponsor: University of Kansas Medical Center • Aim: Disease control
Last updated May 19, 2026 12:01 UTC
-
New test aims to predict falls in muscle disease patients
Knowledge-focused ENROLLING_BY_INVITATIONThis study aims to create a simple test to determine the risk of falling for people with neuromuscular disorders like muscular dystrophy, ALS, and myasthenia gravis. Researchers will evaluate how well a series of physical tasks (like standing up, walking, and balancing) can predi…
Matched conditions: INCLUSION BODY MYOSITIS
Sponsor: LMU Klinikum • Aim: Knowledge-focused
Last updated May 26, 2026 08:51 UTC
-
New study tracks muscle decline in rare disease to unlock clues
Knowledge-focused OngoingThis study follows 150 adults with sporadic inclusion body myositis (sIBM), a rare muscle disease, for two years. Researchers will measure muscle strength, breathing, and swallowing every six months to understand how the disease progresses. No treatments are tested—the goal is to…
Matched conditions: INCLUSION BODY MYOSITIS
Sponsor: University of California, Irvine • Aim: Knowledge-focused
Last updated May 20, 2026 11:53 UTC